Works matching IS 03407004 AND DT 2025 AND VI 74 AND IP 7


Results: 51
    1
    2
    3
    4
    5

    Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04072-6
    By:
    • Pakola, Santeri A.;
    • Ojala, Nea;
    • Kudling, Tatiana V.;
    • Clubb, James H. A.;
    • Jirovec, Elise;
    • van der Heijden, Mirte;
    • Arias, Victor;
    • Haybout, Lyna;
    • Basnet, Saru;
    • Grönberg-Vähä-Koskela, Susanna;
    • Quixabeira, Dafne C. A.;
    • Santos, Joao M.;
    • Cervera-Carrascon, Victor;
    • Hemminki, Otto;
    • Kanerva, Anna;
    • Mustonen, Harri;
    • Puolakkainen, Pauli;
    • Seppänen, Hanna;
    • Hemminki, Akseli
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04060-w
    By:
    • Engels, Pujan;
    • Szolek, Andras;
    • Hörner, Sebastian;
    • Syrigos, Georgios Vavouras;
    • Hebbel, Kim;
    • Schmidtke, Michelle;
    • Zhou, Min;
    • Mateo-Tortola, Maria;
    • Schönfeld, Caroline;
    • Stefanczyk, Sylwia Anna;
    • Wolter, Katharina;
    • Babaei, Sepideh;
    • Schindler, Michael;
    • Claassen, Manfred;
    • Dauch, Daniel;
    • Zender, Lars;
    • Tapía-Abellán, Ana;
    • Weber, Alexander N. R.
    Publication type:
    Article
    16
    17
    18
    19
    20
    21

    Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04032-0
    By:
    • Reischer, Anna;
    • Leutbecher, Alexandra;
    • Hiller, Björn;
    • Perini, Enrico;
    • White, Kieron;
    • Hernández-Cáceres, Alejandra;
    • Schele, Alexandra;
    • Tast, Benjamin;
    • Rohrbacher, Lisa;
    • Winter, Lis;
    • Czogalla, Bastian;
    • Mahner, Sven;
    • Flaswinkel, Heinrich;
    • Leonhardt, Heinrich;
    • Wyder, Lorenza;
    • Wichmann, Christian;
    • Maenner, Denis;
    • Trillsch, Fabian;
    • Kessler, Mirjana;
    • Hopfner, Karl-Peter
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04043-x
    By:
    • Santoni, Matteo;
    • Roviello, Giandomenico;
    • Grande, Enrique;
    • De Giorgi, Ugo;
    • Fiala, Ondrej;
    • Seront, Emmanuel;
    • Molina-Cerrillo, Javier;
    • Pichler, Renate;
    • Myint, Zin W.;
    • Kucharz, Jakub;
    • Kanesvaran, Ravindran;
    • Büttner, Thomas;
    • Pichler, Martin;
    • Basso, Umberto;
    • Kopecky, Jindrich;
    • Bourlon, Maria T.;
    • Cerbone, Linda;
    • Buchler, Tomas;
    • Pinto, Alvaro;
    • de Liaño, Alfonso Gómez
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Efficacy and safety of local–regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04085-1
    By:
    • Li, Shuofeng;
    • Yu, Guanhua;
    • Wang, Mingming;
    • Feng, Shi;
    • Wang, Shanshan;
    • Piao, Mingjian;
    • Li, Chengjie;
    • Zhou, Zixiang;
    • Xun, Ziyu;
    • Sun, Boyu;
    • Li, Jiongyuan;
    • Zhang, Nan;
    • Li, Hu;
    • Yang, Xiaobo;
    • Zhu, Zhenyu;
    • Zhao, Haitao
    Publication type:
    Article
    44

    Efficacy and safety of local–regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04085-1
    By:
    • Li, Shuofeng;
    • Yu, Guanhua;
    • Wang, Mingming;
    • Feng, Shi;
    • Wang, Shanshan;
    • Piao, Mingjian;
    • Li, Chengjie;
    • Zhou, Zixiang;
    • Xun, Ziyu;
    • Sun, Boyu;
    • Li, Jiongyuan;
    • Zhang, Nan;
    • Li, Hu;
    • Yang, Xiaobo;
    • Zhu, Zhenyu;
    • Zhao, Haitao
    Publication type:
    Article
    45
    46
    47
    48

    Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis.

    Published in:
    Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04053-9
    By:
    • Hazim, Antonious;
    • Guiance, Irene Riestra;
    • Shreve, Jacob;
    • Ruan, Gordon;
    • McGlothlin, Damian;
    • LeMahieu, Allison;
    • Haemmerle, Robert;
    • Mcconn, Keith;
    • Godby, Richard C.;
    • Kottschade, Lisa;
    • Schwecke, Anna;
    • Fazer-Posorske, Casey;
    • Peikert, Tobias;
    • Edell, Eric;
    • Leventakos, Konstantinos;
    • Egan, Ashley
    Publication type:
    Article
    49
    50